Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06033599 · ClinicalTrials.gov registry record · Phase 3

Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement

A Phase 3 study of Opioid Use and Tobacco Use, sponsored by Rutgers, The State University of New Jersey.

Recruiting
Registry status
Phase 3
Development phase
420
Enrollment target
2
Study locations

NCT06033599: Recruiting Phase 3 study of Opioid Use and Tobacco Use, sponsored by Rutgers, The State University of New Jersey.

NCT06033599 is a Phase 3 study of Opioid Use and Tobacco Use that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 420 participants, below the 148,256-participant average among 105 other Opioid Use trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06033599, a Phase 3 study of Opioid Use and Tobacco Use, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.

RECRUITING
Registry status
Phase 3
Development phase
420 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to 1) examine barriers and facilitators to implementation of MI and MORE for polysubstance use and evaluate strategies for optimizing training, fidelity, and clinic uptake, and 2) evaluate patient outcomes related to the effectiveness of MORE decreasing opioid, tobacco, and other drug use.

Primary Outcome

Number of days of drug use as measured by self-reported days of use and biochemically verified use via drug screen.

Interventions

  • OTHER MORE and MI and NRT
  • OTHER MORE and No MI and NRT
  • OTHER Support Group and MI and NRT
  • OTHER Support Group and No MI and NRT

Study Locations (2)

New Jersey

  • Rutgers Robert Wood Johnson Medical School - New Brunswick

Utah

  • University of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 420 participants
Start Date 2023-09-05
Est. Completion 2027-06-30
Phase Phase 3

What NCT06033599 shows while recruiting

NCT06033599 is an interventional study that assigns participants to a tested intervention. The registered 420 participants enrollment target is mid-sized for trials with a published cap, below the 148,256-participant average among 105 other Opioid Use trials with a reported enrollment target (100% lower).

The record links to 3 conditions, with Opioid Use appearing as the primary indexed condition, and to 4 interventions - of which MORE and MI and NRT is the first listed.

NCT06033599 reports a single indexed study location in New Jersey, Utah.

Frequently Asked Questions

What is clinical trial NCT06033599 about?

NCT06033599 is a clinical study titled "Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement". The purpose of this study is to 1) examine barriers and facilitators to implementation of MI and MORE for polysubstance use and evaluate strategies for optimizing training, fidelity, and clinic uptake, and 2) evaluate patient outcomes related to the effectiveness of MORE decreasing opioid, tobacco, ...

What is the current status of trial NCT06033599?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 420 participants. The study started on 2023-09-05. Estimated completion is 2027-06-30.

What conditions does trial NCT06033599 study?

This clinical trial studies the following conditions: Opioid Use, Tobacco Use, Polysubstance Abuse.

What interventions are being tested in trial NCT06033599?

The interventions under investigation include: MORE and MI and NRT (OTHER), MORE and No MI and NRT (OTHER), Support Group and MI and NRT (OTHER), Support Group and No MI and NRT (OTHER).

Who is sponsoring clinical trial NCT06033599?

This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06033599 being conducted?

This trial has 2 study locations across New Jersey, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06033599's enrollment target sits among peer trials

420 24th of 105 higher than 82 of 105 other Opioid Use trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Opioid Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01790152 · 420 participants

    Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • NCT02701244 · 420 participants

    A Registry Study of Breast Microseed Treatment

  • NCT02966665 · 420 participants · Phase 1

    : Vascular Function in Health and Disease

  • NCT04149743 · 420 participants · NA

    HEMOTAG® Assessment for Short-term Outcomes of Heart Failure

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06033599, the US trial registry maintained by the National Library of Medicine. NCT06033599 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.